Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

Phase 3 ◽

Asian Patients ◽

Castration Resistant ◽

243PD Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)

Annals of Oncology ◽

10.1093/annonc/mdv524.08 ◽

2015 ◽

Vol 26 ◽

pp. ix71

Author(s):

Y. Sun ◽

H. Shi ◽

C.-H. Chen ◽

J.L. Lee ◽

T.W. Kang ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 3 ◽

Asian Patients ◽

Castration Resistant ◽

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70474-7 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1397-1406 ◽

Cited By ~ 208

Author(s):

Peter Hoskin ◽

Oliver Sartor ◽

Joe M O'Sullivan ◽

Dag Clement Johannessen ◽

Svein I Helle ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Subgroup Analysis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study

European Urology Supplements ◽

10.1016/s1569-9056(13)62445-8 ◽

2013 ◽

Vol 12 (6) ◽

pp. 178

Author(s):

S Nilsson ◽

A.J. Schrader ◽

J. Kliment ◽

A. Solberg ◽

L. Franzén ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 3 ◽

Castration Resistant ◽

Re: Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients with Castration-Resistant Prostate Cancer and Bone Metastases: Results from a Phase 3, Double-Blind, Randomised Trial

The Journal of Urology ◽

10.1016/j.juro.2014.12.077 ◽

2015 ◽

Vol 193 (3) ◽

pp. 847-848

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Randomised Trial ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5070 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5070-5070 ◽

Cited By ~ 1

Author(s):

Chris Parker ◽

Nicholas J. Vogelzang ◽

A. Oliver Sartor ◽

David Bottomley ◽

Robert E. Coleman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Post Treatment ◽

Phase 3 ◽

Castration Resistant ◽

3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e16102 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e16102-e16102 ◽

Cited By ~ 2

Author(s):

Chris Parker ◽

Nicholas J. Vogelzang ◽

A. Oliver Sartor ◽

Robert E. Coleman ◽

Irene Skjorestad ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 3 ◽

Castration Resistant ◽

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

European Urology ◽

10.1016/j.eururo.2017.06.021 ◽

2018 ◽

Vol 73 (3) ◽

pp. 427-435 ◽

Cited By ~ 36

Author(s):

Christopher C. Parker ◽

Robert E. Coleman ◽

Oliver Sartor ◽

Nicholas J. Vogelzang ◽

David Bottomley ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 3 ◽

Cancer Trial ◽

Castration Resistant ◽

Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 Alsympca Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (Crpc) with Bone Metastases (Mets)

Annals of Oncology ◽

10.1093/annonc/mdu336.18 ◽

2014 ◽

Vol 25 ◽

pp. iv264 ◽

Cited By ~ 3

Author(s):

J. Logue ◽

S. Wedel ◽

A. Chodacki ◽

O. Sartor ◽

S. Nilsson ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 3 ◽

Castration Resistant ◽

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30860-x ◽

2019 ◽

Vol 20 (3) ◽

pp. 408-419 ◽

Cited By ~ 89

Author(s):

Matthew Smith ◽

Chris Parker ◽

Fred Saad ◽

Kurt Miller ◽

Bertrand Tombal ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

P078 Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC) patients with symptomatic bone metastases included in the phase 3 ALSYMPCA trial

European Urology Supplements ◽

10.1016/s1569-9056(14)61301-4 ◽

2014 ◽

Vol 13 (5) ◽

pp. 138

Author(s):

B. Mellado ◽

O. Sartor ◽

N.J. Vogelzang ◽

P. Hoskin ◽

S. Nilsson ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Sequential Treatment ◽

Phase 3 ◽

Castration Resistant ◽